The S1P system plays important roles in lymphocyte trafficking and vascular integrity2, and S1P modulators are approved for treating patients with multiple sclerosis and of interest for other conditions with altered brain immune function, such as amyotrophic lateral sclerosis, glioblastoma, and schizophrenia3. Here, MBTPS1 is linked to glioblastoma.